ClinicalHengrui Reports Positive Phase 3 Results for Dual GLP-1/GIP...

Hengrui Reports Positive Phase 3 Results for Dual GLP-1/GIP Agonist HRS9531 in China

-

Hengrui Pharma has released late-stage trial data for its injectable dual GLP-1/GIP receptor agonist, HRS9531, showing the drug led to significant weight reduction in adults with overweight or obesity. The phase 3 study was conducted in China and included 531 adults without diabetes who were administered 2 mg, 4 mg, or 6 mg weekly subcutaneous doses, or placebo.

The topline results indicate that HRS9531 achieved a mean weight reduction of up to 17.7%, or 16.3% after adjusting for placebo. A prespecified supplemental analysis showed that participants receiving the 6 mg dose achieved an average weight loss of 19.2%. The trial met its primary endpoint, with all three dosing groups showing statistically significant weight reduction compared to placebo at 48 weeks.
According to Hengrui, approximately 88% of participants who received HRS9531 achieved at least 5% weight loss, while 44.4% reached a reduction of at least 20%. Most adverse events were gastrointestinal in nature and ranged from mild to moderate in severity.
The phase 3 data follows earlier phase 2 results, where an 8 mg dose of the drug achieved a mean weight loss of 22.8% at 36 weeks. That dose level was not included in the phase 3 study. The drug is being co-developed with Kailera Therapeutics, a U.S.-based company that intends to examine the effects of higher doses and longer treatment durations in global clinical programs.
“We commend our colleagues at Hengrui for these impressive phase 3 clinical results, building on the strong momentum behind HRS9531 (KAI-9531),” said Kailera CEO Ron Renaud. He stated that Kailera is preparing to launch a global clinical development program to further explore the candidate.
The dual agonist is also known as KAI-9531 outside China, where Kailera holds development and commercialization rights. Kailera was launched in October 2024 with $400 million in funding and an initial pipeline that includes HRS9531 and three other obesity-focused therapies. These include KAI-4729, a triple-agonist targeting GLP-1, GIP, and glucagon receptors; KAI-7535, an oral GLP-1 receptor agonist; and an oral formulation of KAI-9531.

Hengrui plans to submit a new drug application in China for HRS9531 for chronic weight management. The full dataset from the phase 3 trial will be presented at an upcoming scientific meeting.
Hong Chen, Head of Metabolism Department I at Hengrui, stated, “The positive data from the HRS9531-301 study demonstrated meaningful, sustained weight loss.” Chen also noted that the company is working to accelerate the development of the drug based on the phase 3 outcomes.

Latest news

A new blood test reveals an early ovarian cancer risk

Early Detection of Ovarian Precancer via Blood Marker The level of CA125 is raised in the blood during ovarian cancer....

According to sources, the US FDA shelving commissioner’s voucher scheme for quick drug reviews

FDA Shelves Fast-Track Drug Voucher Program Former U.S. Food and Drug Administration Commissioner Marty Makary's fast-track drug review program, launched...

Top 10 Technologies Transforming Pharmaceutical Facility Design

Executive Summary Pharmaceutical facility design is evolving as manufacturers respond to increasingly complex production requirements, stricter regulatory expectations, supply chain...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you